Drug intelligence / Profile preview

QDC-101

Development stage: Unknown
Lead developer: Currax Pharmaceuticals

Overview

**QDC-101** is an investigational Currax Pharmaceuticals program for **obesity** that the company identifies as an obesity combination therapy. Currax lists the asset in its development pipeline at Phase 2, but has not publicly disclosed the active components, molecular modality, route of administration, dosage form, or mechanism of action. ([curraxpharma.com](https://www.curraxpharma.com/our-products-pipeline/))

Beyond the preview

Go deeper on QDC-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QDC-101.

Explore the full profile